TSE:5078 stock news
This page provides real-time market news, earnings updates, and company announcements related to CEL Corporation (TSE:5078).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-04-18 06:28 JST
Gilead Snaps Up Arcellx For $115 Per Share - A $7.8 Billion Bet On Cancer Therapy
Finviz2026-02-25 15:13:01
RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here's Why
Finviz2026-02-28 07:24:44
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
Finviz2026-03-03 13:03:52
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Finviz2026-03-05 21:12:18
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
Finviz2026-03-09 11:03:50
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
Finviz2026-03-09 12:03:10
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion
Finviz2026-03-10 07:36:48
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
Finviz2026-03-10 11:07:14
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
Finviz2026-03-11 11:03:53
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Finviz2026-03-12 20:06:49
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
Finviz2026-03-12 20:09:50
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Finviz2026-03-23 11:36:10
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-26 20:03:51
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Finviz2026-03-27 11:03:57
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-03-30 12:03:47
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
Finviz2026-03-30 13:09:49
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
Finviz2026-03-31 12:06:47
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
Finviz2026-04-01 12:51:48
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Finviz2026-04-01 21:15:48
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
Finviz2026-04-06 13:12:04
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
Finviz2026-04-09 12:03:52
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026
Finviz2026-04-09 13:09:53
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
Finviz2026-04-10 20:06:48
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Finviz2026-04-13 11:33:06
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
Finviz2026-03-09 11:03:50
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
Finviz2026-03-09 12:03:10
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion
Finviz2026-03-10 07:36:48
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
Finviz2026-03-10 11:07:14
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
Finviz2026-03-11 11:03:53
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Finviz2026-03-12 20:06:49
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
Finviz2026-03-12 20:09:50
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Finviz2026-03-23 11:36:10
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-26 20:03:51
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Finviz2026-03-27 11:03:57
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-03-30 12:03:47
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
Finviz2026-03-30 13:09:49
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
Finviz2026-03-31 12:06:47
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
Finviz2026-04-01 12:51:48
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Finviz2026-04-01 21:15:48
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
Finviz2026-04-06 13:12:04
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
Finviz2026-04-09 12:03:52
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026
Finviz2026-04-09 13:09:53
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
Finviz2026-04-10 20:06:48
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Finviz2026-04-13 11:33:06
TSE:5078 stock price change
On the last trading day, TSE:5078 stock closed at 4760.00 JPY, with a price change of 0.42% for the day.
Trade stock perpsTSE:5078 stock detailsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more